Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • Internal Medicine • Gastroenterology • General Hepatology
Are you categorically using lenvatinib over sorafenib for unresectable HCC in the absence of contraindications?
Answer from: Medical Oncologist at Community Practice
I have done that is recent patients, yes.
I am doing it because "on paper" I see better PFS and better ORR, of course in addition to the non-inferiority when compared to sorafenib in the randomized trial that is now published.
However, I am building experience with respect to tolerance in my parti...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The REFLECT trial, which demonstrated non-inferiority between lenvatinib and sorafenib in terms of survival, demonstrated an improved response rate with lenvatinib. However, this study enrolled a select patient population, with less than 50% of their liver involved and with good liver function...
Answer from: Medical Oncologist at Academic Institution
To play devil's advocate, I will say no.
While numerically the PFS and ORR may appear higher than Sorafenib, the study was not powered for superiority, thus, one can only truly state that Lenvatinib is not inferior to Sorafenib, not equal.
In regards to ORR observed with Lenvatinib, I do not know ...